Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA7 | P43166 | 6/20 | 0.34 |
| ▸ | CA9 | Q16790 | 6/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.30 |
| ▸ | TUBB | P07437 | 1/20 | 0.30 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055886 | 0.90 | ADRA1A (0.82) | ADRA1APDE4DSMN1; SMN2GAATSHR | |
| SCHEMBL9706734 | 0.89 | ADRA1A (0.79) | ADRA1APDE4DSMN1; SMN2GAATSHR | |
| SCHEMBL8050522 | 0.88 | ADRA1A (0.77) | ADRA1APDE4DSMN1; SMN2GAATSHR | |
| Malotilate SCHEMBL5489569 | 0.87 | ADRA1A (0.75) | ADRA1APDE4D | |
| SCHEMBL9706745 | 0.87 | ADRA1A (0.75) | ADRA1APDE4DMEN1KMT2A | |
| SCHEMBL10614796 | 0.87 | ADRA1A (0.75) | ADRA1APDE4D | |
| SCHEMBL9706771 | 0.86 | ADRA1A (0.74) | ADRA1APDE4DSMN1; SMN2GAACA12 | |
| SCHEMBL9706732 | 0.84 | ADRA1A (0.72) | ADRA1APDE4DSMN1; SMN2GAATSHR | |
| SCHEMBL9674608 | 0.83 | ADRA1A (0.69) | ADRA1APDE4DTSHR | |
| SCHEMBL9706767 | 0.82 | ADRA1A (0.68) | ADRA1APDE4DBCHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1003 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| US-12385916-B2 | Serum metabolic biomarkers and kit for detecting drug-resistant tuberculosis | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2025-08-12 | — | — | US | claimed |
| EP-4494639-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | Pluto Inc. (KR) | 2025-01-22 | — | — | EP | claimed |
| CN-119325992-A | Broad-spectrum plant fungus bactericide | 华中农业大学 | 2025-01-21 | — | — | CN | claimed |
| US-12196753-B2 | Kit for detecting drug-resistant tuberculosis | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2025-01-14 | — | — | US | claimed |
| US-20240295555-A1 | KIT FOR DETECTING DRUG-RESISTANT TUBERCULOSIS | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2024-09-05 | — | — | US | claimed |
| US-20240108644-A1 | TUMOR IMMUNOTHERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-04-04 | — | — | US | claimed |
| US-20230349900-A1 | SERUM METABOLIC BIOMARKERS AND KIT FOR DETECTING DRUG-RESISTANT TUBERCULOSIS | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2023-11-02 | — | — | US | claimed |
| CN-114432334-B | Application of lnc-BIHAA1 in preparation of medicines for preventing and/or treating hepatic fibrosis | 中山大学附属第三医院 | 2023-10-24 | — | — | CN | claimed |
| WO-2023177128-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | 주식회사 플루토 | 2023-09-21 | — | — | WO | claimed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | claimed |
| EP-0134112-B1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF KETOSIS IN LIVESTOCK | NIHON NOHYAKU CO., LTD. (JP) | 1991-04-03 | — | — | EP | claimed |
| US-5001143-A | Pharmaceutical composition for prophylactic and preventive of ketosis of livestocks | NIHON NOHYAKU CO., LTD. (JP) | 1991-03-19 | — | — | US | claimed |
| EP-0238726-A2 | 1,3-Dithio-2-ylidene malonates for curing fat necrosis | NIHON NOHYAKU CO., LTD. (JP) | 1987-09-30 | — | — | EP | claimed |
| EP-0237472-A2 | An ameliorating agent for pulmonary fibrosis and the use thereof | Zyma SA (CH) | 1987-09-16 | — | — | EP | claimed |
| EP-0103206-B1 | FEED COMPOSITION | NIHON NOHYAKU CO., LTD. (JP) | 1986-11-26 | — | — | EP | claimed |
| EP-0134112-A2 | Pharmaceutical composition for prophylaxis or treatment of ketosis in livestock | NIHON NOHYAKU CO., LTD. (JP) | 1985-03-13 | — | — | EP | claimed |
| EP-0103206-A1 | Feed composition | NIHON NOHYAKU CO., LTD. (JP) | 1984-03-21 | — | — | EP | claimed |
| US-4118506-A | LIVER DISORDERS | NIHON NOHYAKU CO., LTD. (JP) | 1978-10-03 | — | — | US | claimed |
| US-4035387-A | FUNGICIDE | NIHON NOHYAKU CO. LTD. (JA) | 1977-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | ADRA1A 1161/4885PDE4D 2626/4885SMN1; SMN2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.